GT Biopharma receives FDA clearance for IND of GTB-3650; Phase 1 trial to start H2 2024

GT Biopharma, Inc.

FDA cleared IND for GTB-3650, an NK cell engager for CD33+ leukemias; Phase 1 trial initiation expected H2 2024.
Initial Phase 1 clinical data for GTB-3650 expected in H1 2025.
GTB-5550 IND submission (B7H3 solid tumors) expected Q1 2025; basket trial in six solid tumor types planned for 2025.
Company becomes fully remote effective July 1, 2024; stockholder communications to San Francisco address.
Cash runway expected to fund operations into 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.